Five-year U.K. breast cancer trial starts

January 16, 2008

Two British charities are joining to initiate the first U.K.-based clinical trial for women with a specific aggressive form of breast cancer.

Breakthrough Breast Cancer and Cancer Research U.K. said the "Triple-Negative Trial" aims to improve breast cancer treatment for women with hormone and HER2 negative tumors, sometimes referred to as triple negative because they lack hormone (oestrogen and progesterone) and HER2 receptors. Such cancers are more common among younger women and those of African ethnicity.

More than 44,000 U.K. women are diagnosed with breast cancer annually, with triple negative tumors accounting for between 15 percent and 20 percent of them. Triple negative tumors do not respond to targeted treatments such as tamoxifen. The new clinical trial is designed to develop a more tailored and effective chemotherapy treatment for such cancers.

The five-year trial will be led by Dr. Andrew Tutt, director of the Breakthrough Breast Cancer Research Unit at King's College London.

Breakthrough Breast Cancer and Cancer Research U.K. are jointly funding the trial with Britain's Institute of Cancer Research and King's College London.

Copyright 2008 by United Press International

Explore further: Hybrid cancer drug could be resistance-resistant

Related Stories

Hybrid cancer drug could be resistance-resistant

May 25, 2016

A team of cancer researchers led by scientists at UC San Francisco and Memorial Sloan Kettering Cancer Center demonstrated in human cells and mouse models that a first-of-its-kind hybrid drug can outsmart drug-resistant cancers.

How a pill could improve breast cancer diagnoses

March 15, 2016

The ongoing debate about breast cancer diagnostics has left many women confused—particularly over what age they should get mammograms and who needs treatment. An issue with current methods is that they often identify lumps ...

Nanoparticles deliver anticancer cluster bombs

March 29, 2016

Scientists have devised a triple-stage "cluster bomb" system for delivering the chemotherapy drug cisplatin, via tiny nanoparticles designed to break up when they reach a tumor.

Boost fundraising with something simple: Sandpaper

March 25, 2016

Not getting enough charitable donations? Try having people to touch sandpaper before you ask for money. A new study shows that touching rough surfaces triggers the emotion of empathy, which motivates people to donate to non-profit ...

Quality of life measures in breast cancer clinical trials

January 7, 2011

Quality of life measures tend to be most useful for clinical decision-making in trials in which quality of life is the primary outcome, according to a recent study published online January 7 in The Journal of the National ...

Recommended for you

Cow embryos reveal new type of chromosome chimera

May 27, 2016

I've often wondered what happens between the time an egg is fertilized and the time the ball of cells that it becomes nestles into the uterine lining. It's a period that we know very little about, a black box of developmental ...

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Shaving time to test antidotes for nerve agents

February 29, 2016

Imagine you wanted to know how much energy it took to bike up a mountain, but couldn't finish the ride to the peak yourself. So, to get the total energy required, you and a team of friends strap energy meters to your bikes ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.